Ex-FDA com­mish Califf joins Cy­to­ki­net­ics’ board just months af­ter big ALS flop

For­mer FDA Com­mis­sion­er Robert Califf is join­ing yet an­oth­er San Fran­cis­co com­pa­ny’s board. Less than a year af­ter ac­cept­ing a board seat at Al­pha­bet’s Ver­i­ly, Califf is of­fer­ing his guid­ance to Cy­to­ki­net­ics $CYTK — a com­pa­ny whose ALS fail­ure made our list of biggest pipeline flops last year.

Be­sides his stint as FDA com­mis­sion­er from 2016 to ear­ly 2017, Califf is the vice chan­cel­lor for health da­ta sci­ence at Duke Health and di­rec­tor of the Duke Uni­ver­si­ty Cen­ter for Health Da­ta Sci­ence. At Ver­i­ly, he was re­cruit­ed to pon­der how ad­vanced com­put­ing would im­prove health care. At Cy­to­ki­net­ics, Califf will bring oth­er ex­pe­ri­ence to the ta­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER